The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always ...
Novartis (NVS) stock dropped 2% as Q1 sales missed estimates at $13.11B. Entresto plunged 42% on generics while CEO warns of ...
Novartis' Q1 2025 results validate our investment thesis. They showcase double-digit sales growth and robust margins, reinforcing our overweight position. Novartis announced a $23 billion US ...
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With ...
Novartis announced late Monday that the U.S. Food and Drug Administration (FDA) approved its Itvisma for certain forms of spinal muscular atrophy (SMA). The healthcare company didn't hesitate to ...
Entrada identified lower-than-expected plasma exposure in juvenile DMD patients as the cause of the lackluster data. Exposure ...
Novartis AG (NYSE: NVS) released data on Thursday from the KALUMA Phase 3 study for the new malaria treatment KLU156 (ganaplacide/lumefantrine, or GanLum). GanLum is ...
Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. However, when you're an income investor, your primary focus is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results